Leerink Partners Reiterates Outperform Rating on Eli Lilly and Company (LLY)

Market Context

Eli Lilly and Company operates in the Healthcare sector. The stock currently trades at $1129.13 with a market capitalization of $906.5B. The stock has gained 32.3% over the past 52 weeks.

Analyst coverage from Leerink Partners provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Eli Lilly and Company.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Eli Lilly and Company

Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jun 25, 2026	Leerink Partners	Outperform	N/A
Jun 09, 2026	Jefferies	Buy	N/A
May 26, 2026	B of A Securities	Buy	N/A
May 05, 2026	Barclays	Overweight	N/A
May 05, 2026	Guggenheim	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View LLY Stock Page